U. Conte

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia

F. Queiroz-Telles, E. Roilides, J. Yan, 2020, The Pediatric infectious disease journal.

A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age

F. Queiroz-Telles, E. Roilides, J. Yan, 2019, The Pediatric infectious disease journal.

Tissue distribution of anidulafungin in neonatal rats.

D. Cross, G. Chmielewski, C. Bowman, 2012, Birth defects research. Part B, Developmental and reproductive toxicology.

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

B. Kullberg, R. Herbrecht, J. Garbino, 2017, The Journal of antimicrobial chemotherapy.

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

M. Galsky, A. Bardia, C. Chappey, 2022, JAMA oncology.

Crizotinib in Patients With MET-Amplified NSCLC.

Jeffrey W. Clark, M. Socinski, G. Shapiro, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Jeffrey W. Clark, S. Ou, S. Ou, 2018 .

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

C. Chappey, D. Hyman, T. Yap, 2019, Journal of Clinical Oncology.

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

M. Tomasson, S. Iida, M. Mohty, 2022, Blood.

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis

Judith M. Martin, M. Capparella, J. Yan, 2016, The Pediatric infectious disease journal.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

M. Tomasson, S. Iida, M. Mohty, 2023, Journal of Clinical Oncology.